Skip to main
GH

GH Stock Forecast & Price Target

GH Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Guardant Health is expected to experience significant growth and profitability in the long term, with their recent inclusion in Unitedhealthcare's commercial coverage plans driving higher price targets from analysts. While they face potential challenges from legal risks and competition, they are investing in new technology and expanding into new markets to drive future growth. Additionally, their strong focus on diversity and sustainability in their workforce positions them well for long-term success. With plans to secure reimbursement for breast cancer and increase adoption of their Shield screening business, they are well-positioned for continued growth and success in the liquid biopsy testing market.

Bears say

Guardant Health is a leader in the liquid biopsy market with strong financial performance in Q1 and a promising pipeline of products and services. However, there are concerns about the sustainability of the company's high prices for its comprehensive genomic profiling (CGP) tests and its potential overreliance on serial testing in the future. Additionally, there are potential risks in the competitive landscape and the accuracy of its CRC testing method.

GH has been analyzed by 23 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Guardant Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Guardant Health Inc (GH) Forecast

Analysts have given GH a Buy based on their latest research and market trends.

According to 23 analysts, GH has a Buy consensus rating as of Sep 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $187.87, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $187.87, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Guardant Health Inc (GH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.